AstraZeneca PLC (AZN) annual results, year to 31 December 2021: revenue USD 37,417 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2021 it reported revenue of USD 37,417 million, up 40.6% on the year before. Its profit attributable to shareholders was USD 112 million, down 96.5%, and diluted earnings per share USD 0.08.
The year to 31 December 2021, against the year before
| Year to | Dec 2020 | Dec 2021 |
|---|---|---|
| Revenue | 26,617 | 37,417 |
| Cost of sales | 5,299 | 12,437 |
| Gross profit | 21,318 | 24,980 |
| Research and development | 5,991 | 9,736 |
| Selling, general and administrative | 11,294 | 15,234 |
| Operating profit | 5,162 | 1,056 |
| Finance costs | 1,306 | 1,300 |
| Profit before tax | 3,916 | -265 |
| Income tax | 772 | -380 |
| Profit for the year | 3,144 | 115 |
| Profit attributable to shareholders | 3,196 | 112 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2020 | Dec 2021 |
|---|---|---|
| Cash from operations | 4,799 | 5,963 |
| Purchase of property, plant and equipment | 961 | 1,091 |
| Free cash flow | 3,838 | 4,872 |
| Dividends paid | 3,572 | 3,856 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2020 | Dec 2021 |
|---|---|---|
| Total assets | 66,729 | 105,363 |
| Equity attributable to shareholders | 15,622 | 39,268 |
| Cash and cash equivalents | 7,832 | 6,329 |
| Borrowings, as filed | 20,380 | 30,781 |
| Lease liabilities | 681 | 987 |
| Trade and other receivables | 7,022 | 9,644 |
| Inventories | 4,024 | 8,983 |
| Goodwill | 11,845 | 19,997 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2020 | Dec 2021 |
|---|---|---|
| Gross margin | 80.1% | 66.8% |
| Operating margin | 19.4% | 2.8% |
| Net margin | 12.0% | 0.3% |
| Free cash flow margin | 14.4% | 13.0% |
| Return on year-end equity | 20.5% | 0.3% |
| Effective tax rate | 19.7% | n/a |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021, this page
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2021, filed 20 February 2024, accession 0001104659-24-025553: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.